1. WHO. Global leprosy update, 2015: time for action, accountability and inclusion. Wkly Epidemiol Rec. 2016; 91:405–420.
2. WHO. Global Leprosy Strategy 2016–2020: Accelerating towards a leprosy-free world. WHO Regional Office for South-East Asia;2016.
4. WHO. Guidelines for the diagnosis, treatment and prevention of leprosy:Full Report. (in press).
5. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966; 34(3):255–273.
6. Sansonetti P, Lagrange PH. The immunology of leprosy:speculations on the leprosy spectrum. Rev Infect Dis. 1981; 3:422–469.
7. Bloom BR, Mehra V. Immunological unresponsiveness in leprosy. Immunol Rev. 1984; 80:5–28.
Article
8. Britton WJ. Immunology of leprosy. Trans R Soc Trop Med Hyg. 1993; 87:508–514.
9. Scollard DM. Time and change: new dimensions in the immunopathologic spectrum of leprosy. Ann Soc Belg Med Trop. 1993; 73:Suppl 1. 5–11.
10. Van Veen NH, Meima A, Richardus JH. The relationship between detection delay and impairment in leprosy control: a comparison of patient cohorts from Bangladesh and Ethiopia. Lepr Rev. 2006; 77:356–365.
Article
11. Bührer-Sékula S, Visschedijk J, Grossi MA, Dhakal KP, Namadi AU, Klatser PR, et al. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev. 2007; 78:70–79.
Article
12. Saunderson P, Gebre S, Desta K, Byass P, Lockwood DN. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev. 2000; 71:285–308.
Article
13. Duthie MS, Orcullo FM, Abbelana J, Maghanoy A, Balagon MF. Comparative evaluation of antibody detection tests to facilitate the diagnosis of multibacillary leprosy. Appl Microbiol Biotechnol. 2016; 100:3267–3275.
Article
14. Martinez AN, Talhari C, Moraes MO, Talhari S. PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic. PLoS Negl Trop Dis. 2014; 8:e2655.
Article
15. Katoch VM. Advances in the diagnosis and treatment of leprosy. Expert Rev Mol Med. 2002; 4:1–14.
Article
16. Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy. J Infect. 2000; 41:137–142.
Article
17. Moet FJ, Pahan D, Oskam L, Richardus JH. COLEP Study Group. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008; 336:761–764.
Article
18. Bobosha K, Tjon Kon Fat EM, van den Eeden SJ, Bekele Y, van der Ploeg-van Schip JJ, de Dood CJ, et al. Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. PLoS Negl Trop Dis. 2014; 8:e2845.
Article
19. Geluk A, Bobosha K, van der Ploeg-van Schip JJ, Spencer JS, Banu S, Martins MV, et al. New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol. 2012; 188:4782–4791.
Article
20. Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect Dis. 2011; 11:26.
Article
21. Penna GO, Bührer-Sékula S, Kerr LRS, Stefani MMA, Rodrigues LC, de Araújo MG, et al. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. PLoS Negl Trop Dis. 2017; 11:e0005725.
Article
22. Manickam P, Mehendale SM, Nagaraju B, Katoch K, Jamesh A, Kutaiyan R, et al. International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes. Indian J Med Res. 2016; 144:525–535.
23. Shen J, Yan L, Yu M, Li J, Yu X, Zhang G. Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China. Int J Dermatol. 2015; 54:315–318.
Article
24. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev. 2007; 78:343–352.
Article
27. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet. 1995; 346:1339–1345.
Article
28. Duthie MS, Pena MT, Ebenezer GJ, Gillis TP, Sharma R, Cunningham K, et al. LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection. NPJ Vaccines. 2018; 3:12.
Article
29. Sharma R, Singh P, Loughry WJ, Lockhart JM, Inman WB, Duthie MS, et al. Zoonotic Leprosy in the Southeastern United States. Emerg Infect Dis. 2015; 21(12):2127–2134.
Article
30. Toh HS, Maharjan J, Thapa R, Neupane KD, Shah M, Baral S, et al. Diagnosis and impact of neuropathic pain in leprosy patients in Nepal after completion of multidrug therapy. PLoS Negl Trop Dis. 2018; 12:e0006610.
Article
31. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, Lockwood DNJ, et al. Erythema Nodosum Leprosum International Study Group. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis. 2017; 11:e0005716.
Article